Mild-to-moderate atopic dermatitis is a chronic inflammatory skin disease often localized to the flexural surfaces of the body and usually begins in childhood. This skin disease affects a large percentage of the world’s population. Atopic dermatitis, commonly known as eczema, is characterized by dry skin, itching, redness, swelling, vesicle formation, cracking, weeping, crusting, and scaling. Atopic dermatitis is a long-term skin disease, which is classified into different types depending on the skin condition such as allergic contact eczema, contact eczema, dyshidrotic eczema, neurodermatitis, nummular eczema, seborrheic eczema, and stasis dermatitis. Multiple factors responsible for atopic dermatitis include seasonal allergies, low humidity, cold weather, and exposure to harsh soaps and detergents. The medication treatment of the skin disease depends on the pattern, duration, and severity of the skin lesions. According to the American Academy of Dermatology (AAD), the atopic dermatitis that emerges in adults is often different and more severe than infants and children. Except drug therapy, atopic dermatitis is treated with ultraviolet light therapy. The ultraviolet light therapy are of two types, which are ultraviolet A and ultraviolet B. According to Anacor Pharmaceuticals, Inc., atopic dermatitis is estimated to affect about 15% to 20% of children in developed countries. The disease often becomes milder with age.
Factors such as new product launch, large patient population, and rapid growth in population are projected to drive the global mild-to-moderate atopic dermatitis treatment market. According to the United Nations Population Fund (UNFPA), the global human population is growing at a rate of 1.1%. Large pipeline products and climatic change are factors which are estimated to fuel the growth of the market globally during the forecast period. On the other hand, generic competition and stringent regulations for product approvals are the factors which are projected to hinder the market growth in the near future.
Request For Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20564
The global mild-to-moderate atopic dermatitis treatment market has been segmented by treatment type, route of administration, distribution channel, and geography. In terms of treatment type, the market is classified into drug treatment and radiation treatment. Drug treatment is further sub-segmented into emollients, antihistamines, antibiotics, corticosteroids, and calcineurin inhibitors. Topical corticosteroids are the standard treatment for most patients with atopic dermatitis for more than 60 years. Calcineurin inhibitors are used as second line treatment drug for atopic dermatitis. In terms of route of administration, the market is classified into topical and oral. Oral medications are offered to patients with severe or treatment-resistant eczema. In terms of distribution channel, the market is classified into hospitals pharmacies, retail pharmacies, and online pharmacies.
Geographically, the mild-to-moderate atopic dermatitis treatment market is distributed over North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=20564
Globally, North America dominates the market owing to new product innovations, lifestyle changes, and early treatment adoption, which in turn are likely to drive the growth of the market. A large proportion of the U.S. population has symptoms of eczema. According to the National Eczema Association in the U.S., 31.6 million people are living with eczema, and the prevalence rate of childhood eczema is 10.7%. Europe is the second leading market for mild-to-moderate atopic dermatitis treatment due to large research and development activities. The Asia Pacific market is expected to grow at a higher rate owing to rapid population growth, large target patient pool, changing lifestyle, adoption of western lifestyle, and growth in research and development. These factor are likely to drive the market growth during the forecast period.
Pre Book Atopic Dermatitis Treatment Market Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=20564<ype=S
The major players operating in this market include Astellas Pharma Inc., Sanofi S.A., Valeant Pharmaceuticals International, Inc., Novartis International AG, Pfizer Inc., Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., and Anacor Pharmaceuticals, Inc.
More Trending Reports by Transparency Market Research
- Synthetic Biology Market : https://www.prnewswire.com/news-releases/development-of-gene-editing-tools-for-treating-genetic-diseases-to-present-immense-growth-opportunities-for-synthetic-biology-market-growth-projected-at-whopping-26-3-cagr-from-2019-to-2027–tmr-301273812.html
- Sepsis Treatment Market : https://www.prnewswire.com/news-releases/mortality-from-covid-19-sepsis-opens-need-for-wealth-of-potential-revenues-in-sepsis-treatment-market-valuation-to-touch-us-1-6-bn-by-2031-tmr-301279042.html
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/
